Current status of blood transfusion and antifibrinolytic therapy in orthopedic surgeries

Nicoleta Stoica1*, Sergio D. Bergese1,2, Wiebke Ackermann1, Kenneth R. Moran1, Charles Hamilton1, Nicholas Joseph3, Nathan Steiner4, Christopher J. Barnett5, Stewart Smith6 and Thomas J. Ellis7

1 Department of Anesthesiology, Wexner Medical Center, Ohio State University, Columbus, OH, USA
2 Department of Neurosurgery, Wexner Medical Center, Ohio State University, Columbus, OH, USA
3 Department of Neuroscience, Ohio State University, Columbus, OH, USA
4 Drexel University College of Medicine, Philadelphia, PA, USA
5 Temple University School of Medicine, Philadelphia, PA, USA
6 College of Medicine, Wexner Medical Center, Ohio State University, Columbus, OH, USA
7 Orthopedic One, Columbus, OH, USA

*Correspondence: nicoleta.stoica@osumc.edu

Keywords: blood transfusion, total hip arthroplasty, direct anterior approach (DAA), posterior approach (PA), tranexamic acid (TXA), erythropoiesis-stimulating agents (ESAs)

INTRODUCTION

The blood loss accompanying orthopedic surgery can be significant, anemia of total hip arthroplasty being a frequent complication. Surgeons have developed different techniques for hip arthroplasty in an effort to reduce morbidity from risks such as infection, blood loss, mobility impairment, and impaired wound healing.

Since the first hip arthroplasty of the modern era was performed, Dr. Charnley’s “low-friction arthroplasty” creating the bases of two-component modern design, various surgical techniques were typically chosen according to surgeons’ personal preferences and local traditions (1). Comparisons of two common techniques, DAA and PA, did not report any conclusive data regarding the superiority of one method to the other (2–6). Among the risks of hip arthroplasty, the need for blood transfusion is a significant one. For the purpose of this review, database searches were performed using the keywords total hip arthroplasty, blood loss, transfusion, posterior approach, and direct anterior approach indicated blood transfusion as an independent risk factor for increased length of hospital stay (LOS), post-operative infections, and post-operative mobility impairment (2,9,10).

The newer DAA techniques are promoted as muscle-sparing and as requiring shorter recovery times (3). Although greater trochanteric intra-operative fracture and lateral femoral cutaneous nerve (LFCN) neuropraxia were more common with the DAA, all patients ultimately recovered without complications (2). Recent publications report several disadvantages associated with the DAA, the most significant being the cost of a special table (approximately $100,000) (4), the need for intra-operative fluoroscopy linked to an extended procedure length and draping contamination, LFCN injury, and bleeding from the circumflex vessels (4,5).

An extensive retrospective analysis published by Christensen et al. in 2014 reviewed anterior and posterior THA procedures performed by a single board-certified orthopedic surgeon between 2003 and 2014. Data collected from 1,793 patients supported previous reports of increased re-intervention rates linked to the DAA (6).

Blood-management techniques in orthopedic surgeries are a ubiquitous subject within the medical literature. However, there is little consensus between anesthesiologists and surgeons on acceptable guidelines and practices (11). Commonly, efforts are made by primary care physicians (PCP), anesthesiologists, and surgeons to detect and treat anemia in patients undergoing elective orthopedic surgeries. Multiple national surveys of blood donations and transfusions within the US, found an increase of 4–5% in allogeneic blood units transfused within the last 15 years (12). Increased awareness of the disadvantages linked to allogeneic blood transfusion (ABT) following orthopedic surgeries has triggered an effort to minimizing its use. A review published by Lemaire in 2008 advised orthopedic surgeons, when performing elective surgeries, to take into consideration the preoperative erythrocyte stock, the anticipated perioperative blood loss, and the acceptable blood loss for a specific patient (13). Based on these reports, increased attention has been placed on the short-term perioperative outcome associated with different techniques used in THA. Martin et al. found that patients who underwent a DAA technique had a shorter LOS and experienced earlier mobilization compared to patients who received the PA. ABT was mentioned as a predictor of mobility failure following THA (2). A similar result was reported by Schweppe et al. while analyzing hospital-related outcomes of the DAA versus the PA in 200 patients (100 per each arm) (14). Recent prospective studies supported previous reports that the DAA results in a decreased LOS despite a longer surgical time with significantly more blood loss (15).

A review and meta-analysis of clinical outcomes including blood loss following total hip arthroplasty performed via the anterior versus posterior approach found no superiority of either method. A lower blood loss associated with the posterior approach was not considered statistically significant (16).
Given the inconsistency of existing data on recent nationwide trends in transfusion following THA, a retrospective cohort study analyzed the data collected from the US nationwide inpatient sample (NIS) for a period of 4 years between 2005 and 2008 and concluded that the incidence of blood transfusions have recently increased (17% over the past 4 years) post-operatively following THA with a great variability in practice (17).

The evidence of ABT reactions led to the development of blood-saving measures (BSMs) including preoperative erythropoietin (EPO) administration and intra- and post-operative autologous blood salvage and reinfusion. A study funded by The Netherlands Organization for Health Research and Development learned that physicians experience barriers to using BSMs due to their techniques, patient safety, and current blood-management policies. Physicians participating in the survey acknowledged using a restrictive transfusion protocol with triggers of hemoglobin threshold as low as 6.4 g/dL. However, recent trials have proved that BSMs are not cost-effective (18, 19). The combination of algorithms for blood management and restrictive transfusion thresholds contribute to surgeons’ “behavioral intention,” and whether a surgeon will tend to “watch and wait” or proceed with transfusion.

Differences of transfusion preferences amongst orthopedic surgeons may result from the necessary balance between managing the consequences of blood loss, and the risks associated with ABT (20). Even though it may be essential to support hemodynamic stability, ABT should be avoided when possible because of its associated risks, including increased rates of infection and LOS (21). A post hoc analysis of data pulled from the regulation of coagulation in orthopedic surgery to prevent deep-venous thrombosis and pulmonary embolism (RECORD) clinical trial program concluded that the rate of any infections and wound inflammation were higher in THA patients receiving ABT compared to patients receiving autologous blood transfusion or no transfusion (21, 22). Alteration of host T-cell regulation and microcirculatory deficits increase the risk of post-operative infection. The overall infection rate for allogeneic recipients was documented as 9.7%. By comparison, patients receiving autologous blood transfusion had a 5.2% infection rate, which is similar to the rate of infection in patients not receiving blood at all. Furthermore, patients receiving ABT had higher rates of surgical site infection and reoperation for suspected acute peri-prosthetic infection (23).

Tranexamic acid (TXA), a synthetic derivative of the amino-acid lysine has been used to reduce blood loss and transfusion requirements in patient undergoing orthopedic surgeries based on its antifibrinolytic properties. By competitively blocking the lysine-binding sites on plasminogen, TXA is able to reduce the local degradation of fibrin by plasmin (24). Conflicting reports of increased risks of deep-vein thrombosis (DVT) in surgical patients receiving TXA led to a recent meta-analysis performed to evaluate the safety and efficacy of its use in major orthopedic surgeries. Encouraging data has shown that blood transfusion volumes per patient were significantly reduced when TXA was used, and the rate of DVT was not affected when compared with controls (25). Topical application is considered to have less systemic absorption and better local effect with the same effectiveness in reducing the blood transfusion rate as IV-TXA (26). Based on the effects of the topical form, Huang et al. published the results of a prospective study using a combination of IV and topically administered TXA in orthopedic surgery [total knee arthroplasties (TKA)]. The study found a better and faster hemostatic effect in the combined group versus the IV-TXA group, because of the higher local concentration of TXA with a smaller maximum decline of hemoglobin (27).

In 1994, Epoetin alpha was approved by the Food and Drug Administration (FDA) for the treatment of anemia associated with chronic kidney disease in order to decrease the need for transfusion. Since then several studies expressed concern over using erythropoiesis-stimulating agents (ESAs) to increase hemoglobin concentrations. These studies suggest that a rapid increase in hemoglobin concentration may trigger hemodynamic instability and serious cardiovascular events (28). Despite the potential concerns, there is data to suggest that the use of ESAs may reduce transfusion rates. A meta-analysis of 26 trials comprising 3,560 patients undergoing hip or knee arthroplasty was published in 2013. The study concluded that ESAs improved post-operative hemoglobin levels with decreased need for ABT. It is important to be aware of the safety concerns associated with ESAs when considering a more cost-effective, alternative method to ABT (29). An analysis of national trends in the utilization of blood transfusion during total hip and knee arthroplasty reported a total of 6,056,655 THA and TKAs performed in the US in the last decade, with an overall transfusion rate of 25.5% for THA and 17.9% for TKA. The records in the NIS showed that 16.4% of the THA patients and 17.9% of TKA patients received an ABT during surgery. Encouragingly, this data also supports evidence that the risk of transfusion-associated HIV and HCV has decreased dramatically within the last decade. The study encouraged the creation and utilization of a blood-management program by targeting groups of patients with a higher risk of blood transfusion in collaboration with PCP (30). A review of overall blood usage at a single, academic medical center in the Boston area found that orthopedic surgeons were frequently unsuccessful in predicting those who would require a transfusion. From a group of 62 TKA patients providing an autologous donation, only 13 required transfusions. The great majority of these autologous donations resulted in wasted resources and expense with blood draw, storage, and retrieval. The study concluded that better models are necessary to predict which patients are at an increased risk for a blood transfusion during the perioperative period. The collected data suggest that the preoperative hematocrit is the most important factor when assessing the need for blood transfusion, additional variables including age, race, gender, BMI, and comorbidities (31).
As we continue to study blood transfusion, we strive to optimize blood management to establish their safety and effectiveness as post-operative transfusion. This strategy intra-operative blood loss and the rate of transfusions have been associated with a reduced transfusions and the use of BSMs. More

CONCLUSION

and orthopedic surgeons (34).

ues to be debated among anesthesiologists generally recognized (31, 33). The hemoglobin patient outcome with reduced ABT is generally (2):455–54. doi:10.1016/j.1999–013–3231–0.

rehabilitation and comparable safety to the posterior approach? Clin Orthop Relat Res (2013) 472(2):455–54. doi:10.1002/1999–013–3231–0.

8. Rathod PA, Orishimo KE, Kremenec II, Deshmukh AJ, Rodriguez JA. Similar improvement in gait parameters following direct anterior & posterior approach total hip arthroplasty. J Arthroplasty (2014) 29(6):1261–4. doi:10.1016/j.arth.2013.11.021.

9. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am (1999) 81(1):2–10.

10. Inthorpe P, Klingler A, Klimmer C, Fries D, Naußbaum W. Risk for postoperative infection after transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic patients undergoing primary arthroplasty. Transfusion (2005) 45(1):103–10. doi:10.1111/j.1537–2995.2005.04149.x

11. Monsel JB, Perna M, Boettemer F. Management of blood products in orthopedic surgery. In: Perioperative Care of the Orthopedic Patient. New York: Springer (2014). p. 311–30.

12. Goodnough LT, Shander A, Brecher ME. Tranfus medicine: looking to the future. Lancet (2003) 361(9352):161–9. doi:10.1016/S0140–6736(03)12195–2

13. Lemaire R. Strategies for blood management in orthopaedic and trauma surgery. J Bone Joint Surg Br (2008) 90B:1128–36. doi:10.1302/00006202X.90B9.21115

14. Schwepe ML, Seyler TM, Plate JF, Swenson RD, Lang JE. Does surgical approach in total hip arthroplasty affect rehabilitation, discharge disposition, and readmission rate? Surg Technol Int (2013) 28:219–27.

15. Barrett WP, Turner SE, Leopold JP. Prospective randomized study of direct anterior vs. posterolateral approach for total hip arthroplasty. J Arthroplasty (2013) 28(9):1634–8. doi:10.1016/j.arth.2013.01.034

16. Higgins BT, Barlow DR, Hegarty NE, Lin TJ, Anterior vs. posterior approach for total hip arthroplasty, a systematic review and meta-analysis. J Arthroplasty (2014). doi:10.1016/j.arth.2014.10.020

17. Browne JA, Adib F, Brown TE, Novicki WM. Transfusion rates are increasing following total hip arthroplasty: risk factors and outcomes. J Arthroplasty (2013) 28(8 Suppl):34–7. doi:10.1016/j.arth.2013.03.035

18. Voorn VM, Marang-van de Mheen PJ, Wentink MM, Kapten AA, Koopman-van Gemert AW, So–Oman C, et al. Perceived barriers among physicians for stopping non-cost-effective blood-saving measures in total hip and total knee arthroplasties. Transfus (2014) 54(10 Pt 2):2598–607. doi:10.1111/trf.12672

19. Covrett C, Laffon M, Baud A, Payen V, Burdin P, Fussiardi J. A restrictive use of both autologous donation and recombinant human erythropoietin is an efficient policy for primary total hip or knee arthroplasty. Anesth Analg (2004) 99(1):262–71. doi:10.1095/01.ANE.0000018165.70570.78

20. Francis JJ, Timmounth A, Stanworth SJ, Grimshaw JM, Johnston M, Hyde C, et al. Using theories of behaviour to understand transfusion prescribing in three clinical contexts in two countries: development work for an implementation trial. Implement Sci (2009) 4:70. doi:10.1186/1748–5908–4–70

21. Borghi B, Casati A. Incidence and risk factors for allogeneic blood transfusion during major joint replacement using an integrated autotransfusion regimen. The Rizzoli Study Group on Orthopedic Anesthesia. Eur J Anesthesiol (2000) 17(7):411–7. doi:10.1046/j.1365–2364.2000.00693.x

22. Friedman R, Homering M, Helberg G, Berkowitz SD. Allogeneic blood transfusions and postoperative infections after total hip or knee arthroplasty. J Bone Joint Surg Am (2014) 96(4):272–8. doi:10.2106/JBJS.L.01268

23. Newman ET, Watters TS, Lewis JS, Jennings JM, Wellman SS, Attarian DE, et al. Impact of perioperative allogeneic and autologous blood transfusion on acute wound infection following total knee and total hip arthroplasty. J Bone Joint Surg Am (2014) 96(4):279–84. doi:10.2106/JBJS.L.01041

24. McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolytic. Drugs (2012) 72(5):385–617. doi:10.2165/11290970–000000000–00000

25. Huang F, Wu D, Ma G, Yin Z, Wang Q. The use of tranexamic acid to reduce blood loss and transfusion in major orthopedic surgery: a meta-analysis. J Surg Res (2016) 168:318–27. doi:10.1016/j.jss.2015.08.020

26. Kaury S, Mason J, Vaghela M, Sarda P, Nargol A, Maheswaran S, et al. Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement. J Bone Joint Surg Am (2013) 95(21):1961. doi:10.2106/JBJS.L.09097

27. Huang Z, Ma J, Shen B, Pei E. Combination of intravenous and topical application of tranexamic acid in primary total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty (2014) 29(12):2342–6. doi:10.1016/j.arth.2014.05.026

28. Ungur EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents – time for a reevaluation. N Engl J Med (2010) 362(3):189–92. doi:10.1056/NEJMoa0912328

29. Alaseh K, Alotaibi GS, Almoodamegh AH, Alseman AA, Kouroukis CT. The use of peropera- tive erythropoiesis-stimulating agents (ESA) in patients who underwent knee or hip arthroplasty. J Arthroplasty (2013) 28(9):1463–72. doi:10.1016/j.arth.2013.01.024

30. Yoshizawa H, Yoneoka D. National trends in the utili- zation of blood transfusions in total hip and knee arthroplasty. J Arthroplasty (2014) 29(10 Pt 2):1935–7. doi:10.1016/j.arth.2014.04.029

31. Robinson S, McGonigle O, Volin S, Sung YC, Moore M, Cassidy C, et al. Comprehensive look at blood transfusion utilization in total joint arthroplasty at a single academic medical center under a single surgeon. J Blood Transfus (2013) 2013:83250. doi:10.1155/2013/83250

32. Spahn DR. Anemia and patient blood manage- ment in hip and knee surgery. Anesthesi- ology (2010) 113(2):482–95. doi:10.1097/ALN.0b013e3181e08697

33. Horstmann WG, Ettema HB, Verheyen CC. Dutch orthopedic blood management surveys 2002 and

www.frontiersin.org

February 2015 | Volume 2 | Article 3 | 3

Stoicea et al. Current status of blood transfusion in orthopedic surgeries

requiring more than two units of autologous blood. The study found that BMI was not predictive of infection risk (32).

Multiple surveys addressed to Dutch and UK orthopedic surgeons within the last decade revealed an increased awareness and a positive attitude toward perioperative BSMs. The need for perioperative blood management directed toward improving patient outcome with reduced ABT is generally recognized (31, 33). The hemoglobin threshold warranting transfusion continues to be debated among anesthesiologists and orthopedic surgeons (34).
2007: an increasing use of blood-saving measures. Arch Orthop Trauma Surg (2010) 130(1):55–9. doi:10.1007/s00402-009-0910-0
34. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med (2011) 365(26):2453–62. doi:10.1056/NEJMoa1012452

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 04 January 2015; paper pending published: 12 January 2015; accepted: 22 January 2015; published online: 12 February 2015.
Citation: Stoicea N, Bergese SD, Ackermann W, Moran KR, Hamilton C, Joseph N, Steiner N, Barnett CJ, Smith S and Ellis TJ (2015) Current status of blood transfusion and antifibrinolytic therapy in orthopedic surgeries. Front. Surg. 2:3. doi: 10.3389/fsurg.2015.00003

This article was submitted to Orthopedic Surgery, a section of the journal Frontiers in Surgery. Copyright © 2015 Stoicea, Bergese, Ackermann, Moran, Hamilton, Joseph, Steiner, Barnett, Smith and Ellis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.